On the FN, in correlation with the migration results (Fig. 6b), Infliximab addition resulted in a modest reduction in COL1A and ACTA2 levels (fold change of IPF-SN vs. control-FN: 0.78 ± 0.09 (p = 0.05) and 0.79 ± 0.17 (NS) for COL1A and ACTA2, respectively, n = 4). This evidence concerns the gene ACTA2 and idiopathic pulmonary fibrosis.